Amneal Pharmaceuticals, Inc.
AMRXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Amneal Pharmaceuticals, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in. At a $7.13B market cap, Amneal Pharmaceuticals, Inc. ranks as a mid-cap company within healthcare. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Market Cap
$7.13B
Beta
1.22
P/E (TTM)
40.96
P/E (Fwd)
17.02
EPS (TTM)
$0.50
EPS (Fwd)
$1.20
ROE
613.0%
ROA
8.6%
Cash
$131.4M
Total Debt
$2.79B
Free CF
-$115.3M
52W Change
96.5%
Annual Financials
Cash vs Debt
Where AMRX stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, AMRX finished 27.42% above its 150-day moving average ($15.72) and 31.52% above its 200-day moving average ($15.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMRX overbought or oversold?
At the October 13, 2026 close, AMRX's RSI(14) was 58.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, AMRX has $131.4M in cash with $2.79B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$115.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 613.0%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.21B (2022) to $3.02B (2025), reflecting a 36% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing AMRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.